Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Oct 31, 2025 | (Q1)Jul 31, 2025 | (FY)Apr 30, 2025 | (Q4)Apr 30, 2025 | (Q3)Jan 31, 2025 | (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (FY)Apr 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||||||
| Cash flow from continuing operating activities | -583.45%-1.79M | -1,113.70%-1.96M | -61,114.53%-3.86M | -1.17M | -2.26M | -262.05K | -161.44K | -2,603.43%-6.3K | -233 |
| Net income from continuing operations | -1,894.12%-3.61M | -736.89%-2.65M | -13,096.51%-8.49M | ---5.59M | ---2.41M | ---181.1K | ---316.85K | -27,408.55%-64.37K | ---234 |
| Asset impairment expenditure | ---- | ---- | --3.66M | ---- | ---- | ---- | ---- | ---- | ---- |
| Remuneration paid in stock | 135,108.21%2.42M | 27,612.39%93.95K | --1.58M | --821.57K | --754.31K | --1.79K | --339 | ---- | ---- |
| Other non cashItems | ---- | ---- | --311.03K | --30.89K | --125.12K | --0 | --155.03K | ---- | ---- |
| Change In working capital | -655.66%-625.21K | 1,329,620.00%598.37K | -1,665.69%-909.21K | ---97.85K | ---728.67K | ---82.74K | --45 | 5,807,000.00%58.07K | --1 |
| -Change in receivables | ---68.29K | --14.48K | ---44.66K | ---- | ---- | --0 | --0 | ---- | ---- |
| -Change in prepaid assets | ---593K | --497.71K | -16,572.58%-1.01M | ---248.98K | ---758.05K | --0 | --0 | ---6.04K | --0 |
| -Change in payables and accrued expense | 143.61%36.08K | 191,406.67%86.18K | 122.23%142.48K | --195.79K | --29.38K | ---82.74K | --45 | 6,411,000.00%64.11K | --1 |
| Cash from discontinued investing activities | |||||||||
| Operating cash flow | -583.45%-1.79M | -1,113.70%-1.96M | -61,114.53%-3.86M | ---1.17M | ---2.26M | ---262.05K | ---161.44K | -2,603.43%-6.3K | ---233 |
| Investing cash flow | |||||||||
| Cash flow from continuing investing activities | 0 | 0 | 99.06K | 7.85K | 0 | 0 | 91.21K | ||
| Net business purchase and sale | --0 | --0 | --99.06K | --7.85K | --0 | --0 | --91.21K | ---- | ---- |
| Cash from discontinued investing activities | |||||||||
| Investing cash flow | --0 | --0 | --99.06K | --7.85K | --0 | --0 | --91.21K | ---- | ---- |
| Financing cash flow | |||||||||
| Cash flow from continuing financing activities | 778.14%1.94M | 2,143.15%1.79M | 5,425.92%4.42M | 866.44K | 3.25M | 220.5K | 79.84K | 326.67%80K | 18.75K |
| Net issuance payments of debt | ---- | ---- | ---18.26K | ---- | ---- | ---- | ---- | ---- | ---- |
| Net common stock issuance | 988.43%2.4M | --0 | 5,124.80%4.18M | --1.6M | --2.28M | --220.5K | --79.84K | 326.67%80K | --18.75K |
| Proceeds from stock option exercised by employees | --67K | --1.39M | --379.25K | --284.7K | --94.55K | --0 | --0 | ---- | ---- |
| Net other financing activities | ---530.7K | --400K | ---120.1K | ---1M | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | |||||||||
| Financing cash flow | 778.14%1.94M | 2,143.15%1.79M | 5,425.92%4.42M | --866.44K | --3.25M | --220.5K | --79.84K | 326.67%80K | --18.75K |
| Net cash flow | |||||||||
| Beginning cash position | 106.19%943.26K | 148.24%1.11M | 2,318.62%447.86K | --1.41M | --415.92K | --457.47K | --447.86K | --18.52K | --0 |
| Current changes in cash | 449.85%145.34K | -1,853.07%-168.49K | 800.79%663.89K | ---299.9K | --995.73K | ---41.55K | --9.61K | 298.02%73.7K | --18.52K |
| End cash Position | 161.73%1.09M | 106.19%943.26K | 1,105.57%1.11M | --1.11M | --1.41M | --415.92K | --457.47K | 398.02%92.22K | --18.52K |
| Free cash from | -583.45%-1.79M | -1,113.70%-1.96M | -61,114.53%-3.86M | ---1.17M | ---2.26M | ---262.05K | ---161.44K | -2,603.43%-6.3K | ---233 |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.